Literature DB >> 2784459

Endotoxemia elicits increased circulating beta 2-IFN/IL-6 in man.

Y Fong1, L L Moldawer, M Marano, H Wei, S B Tatter, R H Clarick, U Santhanam, D Sherris, L T May, P B Sehgal.   

Abstract

beta 2-IFN/hepatocyte stimulating factor/IL-6 is a cytokine secreted by monocytes, fibroblasts, and endothelial cells in cell culture that possesses diverse biologic activity including the stimulation of acute phase plasma protein synthesis and immunomodulation. The circulating levels of this cytokine in man in response to bacterial LPS (endotoxin) were studied. A single i.v. bolus of endotoxin (20 U/kg) produced a monophasic rise in circulating immunoreactive IFN-beta 2/IL-6 and IFN-beta 2/IL-6 bioactivity (hepatocyte stimulation and B cell differentiation assays) peaking 2 to 4 h after the endotoxin challenge. Peak IFN-beta 2/IL-6 levels ranged from 4.1 to 27.5 ng/ml. Associated with this was a rise in circulating C-reactive protein levels detected 20 h after the endotoxin bolus. Thus, IFN-beta 2/IL-6 is likely one of the endogenous mediators which is triggered in man during bacterial infection and likely participates in the metabolic and immune responses of the infected host.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2784459

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  76 in total

Review 1.  New insights into the biology of the acute phase response.

Authors:  A F Suffredini; G Fantuzzi; R Badolato; J J Oppenheim; N P O'Grady
Journal:  J Clin Immunol       Date:  1999-07       Impact factor: 8.317

Review 2.  Primary biliary cirrhosis. Connecting molecular biology to clinical medicine.

Authors:  S Reynoso-Paz; R L Coppel; Y Nakanuma; M E Gershwin
Journal:  Clin Rev Allergy Immunol       Date:  2000-04       Impact factor: 8.667

3.  On the mechanism for efficient repression of the interleukin-6 promoter by glucocorticoids: enhancer, TATA box, and RNA start site (Inr motif) occlusion.

Authors:  A Ray; K S LaForge; P B Sehgal
Journal:  Mol Cell Biol       Date:  1990-11       Impact factor: 4.272

Review 4.  Interleukin-6 and the acute phase response.

Authors:  P C Heinrich; J V Castell; T Andus
Journal:  Biochem J       Date:  1990-02-01       Impact factor: 3.857

5.  Selective and early increase of IL-1 inhibitors, IL-6 and cortisol after elective surgery.

Authors:  F Di Padova; C Pozzi; M J Tondre; R Tritapepe
Journal:  Clin Exp Immunol       Date:  1991-07       Impact factor: 4.330

6.  Requirements for tumor necrosis factor-alpha and interleukin-1 in limb ischemia/reperfusion injury and associated lung injury.

Authors:  A Seekamp; J S Warren; D G Remick; G O Till; P A Ward
Journal:  Am J Pathol       Date:  1993-08       Impact factor: 4.307

7.  Serum soluble interleukin 6 (IL-6) receptor and IL-6/soluble IL-6 receptor complex in systemic juvenile rheumatoid arthritis.

Authors:  F De Benedetti; M Massa; P Pignatti; S Albani; D Novick; A Martini
Journal:  J Clin Invest       Date:  1994-05       Impact factor: 14.808

8.  Ca2+ responses to interleukin 1 and tumor necrosis factor in cultured human skin fibroblasts. Possible implications for Reye syndrome.

Authors:  B E Corkey; J F Geschwind; J T Deeney; D E Hale; S D Douglas; L Kilpatrick
Journal:  J Clin Invest       Date:  1991-03       Impact factor: 14.808

9.  A mouse model for investigating the molecular pathogenesis of adenovirus pneumonia.

Authors:  H S Ginsberg; L L Moldawer; P B Sehgal; M Redington; P L Kilian; R M Chanock; G A Prince
Journal:  Proc Natl Acad Sci U S A       Date:  1991-03-01       Impact factor: 11.205

10.  Defective production of interleukin-6 in very small premature infants in response to bacterial pathogens.

Authors:  A Yachie; N Takano; K Ohta; T Uehara; S Fujita; T Miyawaki; N Taniguchi
Journal:  Infect Immun       Date:  1992-03       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.